Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Editorials
You have accessRestricted Access

What Is the Role of Vitamin D Supplementation on Vascular Health in CKD?

Nigel D. Toussaint and Irene Ruderman
CJASN September 2017, 12 (9) 1377-1379; DOI: https://doi.org/10.2215/CJN.07170717
Nigel D. Toussaint
*Department of Nephrology, The Royal Melbourne Hospital, Parkville, Victoria, Australia; and
†Department of Medicine at Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irene Ruderman
*Department of Nephrology, The Royal Melbourne Hospital, Parkville, Victoria, Australia; and
†Department of Medicine at Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading
  • Dietary Supplements
  • Nutrition Therapy
  • Vitamin D
  • Renal Insufficiency
  • Chronic
  • Vitamin D Deficiency

The importance of synthesis of 1,25 dihydroxyvitamin D or 1,25[OH]2D (calcitriol) in the kidney is well documented, and alterations in vitamin D metabolism, ubiquitous in patients with CKD, are a key feature of CKD mineral and bone disorder (CKD-MBD). The progressive decrease in calcitriol synthesis with CKD, and subsequent development of secondary hyperparathyroidism (SHPT), is an active process primarily mediated by the counter-regulatory effects of increasing levels of the phosphaturic hormone, fibroblast growth hormone 23.

Availability of 1-α hydroxylase (also known as CYP27B1), a key enzyme involved in the conversion of 25-hydroxyvitamin D (25[OH]D) to 1,25(OH)2D, is reduced as kidney mass declines. This enzyme is highly dependent on the substrate 25(OH)D, and reduced availability of this substrate in patients with CKD also has an important role in 1,25(OH)2D deficiency and SHPT. Reduced sun exposure, impaired skin synthesis of vitamin D, and dietary restrictions contribute to the high prevalence of 25(OH)D deficiency in CKD.

There is a growing body of evidence showing that vitamin D is pivotal to good health in the CKD population. The biologic effects of vitamin D extend beyond calcium metabolism in experimental and epidemiologic data. Observational studies report vitamin D deficiency is associated with hypertension, cardiovascular disease and mortality, in both the general population (1) and patients with CKD (2), and therefore may be a potentially modifiable cardiovascular risk factor. One meta-analysis reported increased mortality in patients with CKD with a relative risk of 0.86 (95% confidence interval, 0.82 to 0.91) per 10 ng/ml decrease in 25(OH)D levels (2); another suggested vitamin D replacement confers a 27% (95% confidence interval, 8 to 56%) risk reduction in cardiovascular mortality when administered to patients with CKD (3). Vitamin D deficiency has been implicated in endothelial dysfunction and in vitro studies demonstrate treatment with vitamin D analogs abrogates osteogenic processes and inhibits mineralization in vascular smooth muscle cells (4), as well as having anti-inflammatory effects (5).

Active vitamin D therapy (calcitriol or vitamin D analogs) has been the predominant treatment for SHPT in patients with CKD for many decades. This therapy inhibits parathyroid hormone (PTH) secretion via the vitamin D receptor and, in addition to tissues involved in mineral homeostasis, this receptor has been identified in many organs including vascular smooth muscle, endothelial cells, and cardiac tissue.

Nutritional vitamin D supplementation with vitamin D2 (ergocalciferol) or vitamin D3 (cholecalciferol) has not been as extensively or systematically investigated in the CKD population, and clinical trial evidence of its effect on cardiovascular risk or outcomes in patients with CKD is lacking. Recent studies have reported the effectiveness of calcifediol, a vitamin D prohormone, to treat SHPT (6). Calcifediol, also called calcidiol or 25(OH)D, is converted to calcitriol by CYP27B1 and inhibits the catabolism of both 25(OH)D and 1,25(OH)2D, thus increasing levels of both. Few studies, however, have assessed benefits of calcifediol beyond mineral metabolism in patients with CKD.

Numerous experimental studies have supported the potential effect of vitamin D on vascular tone, including altered vascular oxidative stress and smooth muscle function, and multiple clinical trials have explored the effects of vitamin D therapy (nutritional and active vitamin D) on surrogate markers of cardiovascular risk in patients with CKD, including several studies involving assessment of vascular stiffness. Vitamin D induces concentration dependent increases in endothelial nitric oxide production (7), and small observational and case control studies report an improvement in endothelial function with vitamin D supplementation (8). There is inconsistent evidence to date, however, to suggest that vitamin D improves indicators of vascular function and arterial stiffness, and this may relate to the heterogeneity in study designs (9). With conflicting literature, more evidence is needed to examine the hypothesis that vascular tone could be the physiologic mechanism by which vitamin D confers cardiovascular protection in CKD.

In this issue of the Clinical Journal of the American Society of Nephrology (CJASN), two randomized controlled trials (RCTs) are presented exploring the effects of vitamin D therapy on vascular function. Although both had only moderate-sized study cohorts and relatively short follow-up periods, both studies are extremely well conducted clinical trials, novel and unique in their study designs, and provide further understanding on the pleiotropic effects of vitamin D on numerous tissues, including endothelial and vascular smooth muscle cells.

Firstly, Levin et al. (10) report a double-blind placebo-controlled trial to assess the effectiveness of vitamin D supplementation on pulse wave velocity (PWV). PWV, a marker of arterial stiffness, is affected by endothelial and smooth muscle function, fibrous tissue and calcification, and is an independent predictor of cardiovascular disease and mortality. Levin et al. (10) compared fixed doses of oral calcifediol (5000 IU), calcitriol (0.5 μg) or placebo, administered three times weekly for 6 months, in 119 patients with CKD stages 3b and 4. Study medication was given irrespective of 25(OH)D levels and all study participants received renin-angiotensin-aldosterone system blockers. Despite randomization, there was an imbalance in baseline PWV measurements, with higher readings in the placebo arm, although adjustments were made in the analyses for this discrepancy. In the 87 participants who completed the study, a decrease in PWV was observed in the calcifediol group, with no change in the calcitriol group and an increase in those on placebo. Although potentially underpowered on the basis of the investigators’ initial sample size calculation, with a moderately high attrition rate for a 6-month study, Levin et al. (10) report that PWV was significantly different between combined vitamin D groups (mean change, −0.4; 95% confidence interval, −1.2 to 0.4 m/s) and placebo (mean change, +1.1; 95% confidence interval, −0.1 to 2.2 m/s).

A reduction in PTH was observed in both the calcifediol and calcitriol groups, and 25(OH)D levels were significantly elevated with calcifediol, but not with calcitriol. These findings are consistent with known effects of these vitamin D agents because calcifediol does not induce CYP24A1 (an enzyme which readily catabolizes 25[OH]D and 1,25[OH]2D), unlike calcitriol. It is difficult to distinguish the effect of vitamin D supplementation or change in PTH levels on the improvement in PWV in this study, although participants who achieved the highest 25(OH)D levels at the end of the 6-month period were those with a significant decrease in PWV.

In the second RCT, Kendrick et al. (11) compared the effects of oral calcitriol and cholecalciferol on another surrogate marker of vascular health, flow-mediated dilation (FMD). FMD, which reflects endothelium-dependent and nitric oxide–mediated arterial function, is a noninvasive approach to examine vasodilator function in vivo. Kendrick et al. (11) assessed 128 patients, again with CKD stages 3b and 4, but with vitamin D deficiency, defined as 25(OH)D levels <30 ng/ml. In this double-blinded study, participants were randomized to receive either oral cholecalciferol (4000 IU daily for 1 month, then 2000 IU daily) or calcitriol (0.25 μg daily for 1 month, then 0.5 μg daily). Brachial FMD and endothelium-independent dilation were performed at baseline and 6 months. At study end, in the 115 participants who completed the trial, there was no difference in FMD between the two arms or changes in brachial arterial dilation to nitroglycerin, in contrast to investigators’ hypothesis that calcitriol would be more effective than cholecalciferol. There was also no change in total vascular endothelial cell expression of NFκB or in markers of inflammation. Given that many of these factors are potential mechanisms for the development and progression of left ventricular hypertrophy, the negative findings in this study may explain why recent RCTs assessing the effect of vitamin D therapy on this cardiac end point have not proved to be positive (12,13).

As expected, Kendrick et al. (11) showed a significant reduction of PTH in the calcitriol group, although not with cholecalciferol, and 25(OH)D levels increased with cholecalciferol, although not calcitriol. An increase in fibroblast growth hormone 23 was reported in both arms and, as expected, there was a reduction in albuminuria with calcitriol, consistent with prior evidence that active vitamin D reduces proteinuria (14). Of note, only two thirds of participants were taking renin-angiotensin-aldosterone system blockers in this study.

Levin et al. (10) and Kendrick et al. (11) should be commended for their important RCTs, further adding to our understanding of vitamin D and vascular health; however, there remains uncertainty about the effectiveness of vitamin D supplementation on vascular endpoints in patients with CKD, as not all results are consistent with previously published studies. Other RCTs have reported benefits of vitamin D on FMD in patients with CKD, including the Paricalcitol and Endothelial Function in Chronic Kidney Disease trial with paricalcitol (15), and another more recent trial in this month’s issue of the Journal of the American Society of Nephrology (16). Kumar et al. (16) studied 120 nondiabetic participants with CKD stages 3 and 4 and vitamin D deficiency (25[OH]D levels ≤20 ng/ml) and assessed the effect of cholecalciferol (300,000 IU administered at baseline and 8 weeks) compared with placebo on FMD over 16 weeks. FMD was increased with cholecalciferol but not with placebo, and changes correlated with 25(OH)D levels, findings in contrast to the RCT by Kendrick et al. (11), although the latter did not involve a placebo arm. Kumar et al. (16) also reported a benefit of vitamin D therapy on nitroglycerin-mediated dilation and on PWV, the latter finding consistent with results of the RCT by Levin et al. (10).

The RCTs in this edition of CJASN are timely with the recent publication of the updated Kidney Disease Improving Global Outcomes CKD-MBD clinical guidelines (17). The safety of active vitamin D therapy in patients who are predialysis, with the risk of hypercalcemia and potential promotion of vascular calcification, remains a concern as highlighted in recent RCTs (12,13). Kendrick et al. (11) also reported higher rates of hypercalcemia as well as hyperphosphatemia, with 11% of participants in the calcitriol arm commenced on phosphate binders during the study period. This concern with active vitamin D therapy has resulted in the revision of recommendations by the Kidney Disease Improving Global Outcomes CKD-MBD work group, with administration of calcitriol and vitamin D analogs now not routinely recommended in patients who are predialysis, unless for the treatment of severe and progressive SHPT (17).

The potential effect of vitamin D supplementation on vascular endothelial and smooth muscle function in patients with CKD continues to be of significant interest. Despite the excellent studies presented in this edition of CJASN, we remain in the dark regarding optimal thresholds for vitamin D replacement, and preferred formulations and doses to affect vascular health. However, current evidence would generally support cardiovascular benefits of improved vascular compliance and endothelial-dependent vasodilation with any vitamin D supplementation (cholecalciferol, calcifediol, or active vitamin D) in patients with CKD, with advantages on vascular health perhaps outweighing potential harms of these medications. Future clinical trials may need to focus on graduated dose increases of vitamin D supplementation and pharmacodynamic data in combination with hard cardiovascular clinical outcomes to further inform clinical practice.

Disclosures

None.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • See related articles, “Randomized Controlled Trial for the Effect of Vitamin D Supplementation on Vascular Stiffness in CKD,” and “Cholecalciferol, Calcitriol, and Vascular Function in CKD: A Randomized, Double-Blind Trial,” on pages 1447–1460 and 1438–1446, respectively.

  • Copyright © 2017 by the American Society of Nephrology

References

  1. ↵
    1. Zittermann A,
    2. Iodice S,
    3. Pilz S,
    4. Grant WB,
    5. Bagnardi V,
    6. Gandini S
    : Vitamin D deficiency and mortality risk in the general population: A meta-analysis of prospective cohort studies. Am J Clin Nutr 95: 91–100, 2012
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Pilz S,
    2. Iodice S,
    3. Zittermann A,
    4. Grant WB,
    5. Gandini S
    : Vitamin D status and mortality risk in CKD: A meta-analysis of prospective studies. Am J Kidney Dis 58: 374–382, 2011
    OpenUrlCrossRefPubMed
  3. ↵
    1. Duranton F,
    2. Rodriguez-Ortiz ME,
    3. Duny Y,
    4. Rodriguez M,
    5. Daurès JP,
    6. Argilés A
    : Vitamin D treatment and mortality in chronic kidney disease: A systematic review and meta-analysis. Am J Nephrol 37: 239–248, 2013
    OpenUrlCrossRefPubMed
  4. ↵
    1. Aoshima Y,
    2. Mizobuchi M,
    3. Ogata H,
    4. Kumata C,
    5. Nakazawa A,
    6. Kondo F,
    7. Ono N,
    8. Koiwa F,
    9. Kinugasa E,
    10. Akizawa T
    : Vitamin D receptor activators inhibit vascular smooth muscle cell mineralization induced by phosphate and TNF-α. Nephrol Dial Transplant 27: 1800–1806, 2012
    OpenUrlCrossRefPubMed
  5. ↵
    1. Martinez-Moreno JM,
    2. Herencia C,
    3. Montes de Oca A,
    4. Muñoz-Castañeda JR,
    5. Rodríguez-Ortiz ME,
    6. Díaz-Tocados JM,
    7. Peralbo-Santaella E,
    8. Camargo A,
    9. Canalejo A,
    10. Rodriguez M,
    11. Velasco-Gimena F,
    12. Almaden Y
    : Vitamin D modulates tissue factor and protease-activated receptor 2 expression in vascular smooth muscle cells. FASEB J 30: 1367–1376, 2016
    OpenUrlCrossRefPubMed
  6. ↵
    1. Sprague SM,
    2. Crawford PW,
    3. Melnick JZ,
    4. Strugnell SA,
    5. Ali S,
    6. Mangoo-Karim R,
    7. Lee S,
    8. Petkovich PM,
    9. Bishop CW
    : Use of extended-release calcifediol to treat secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Am J Nephrol 44: 316–325, 2016
    OpenUrlCrossRefPubMed
  7. ↵
    1. Molinari C,
    2. Uberti F,
    3. Grossini E,
    4. Vacca G,
    5. Carda S,
    6. Invernizzi M,
    7. Cisari C
    : 1α,25-dihydroxycholecalciferol induces nitric oxide production in cultured endothelial cells. Cell Physiol Biochem 27: 661–668, 2011
    OpenUrlCrossRefPubMed
  8. ↵
    1. Chitalia N,
    2. Ismail T,
    3. Tooth L,
    4. Boa F,
    5. Hampson G,
    6. Goldsmith D,
    7. Kaski JC,
    8. Banerjee D
    : Impact of vitamin D supplementation on arterial vasomotion, stiffness and endothelial biomarkers in chronic kidney disease patients. PLoS One 9: e91363, 2014
    OpenUrlCrossRefPubMed
  9. ↵
    1. Rodríguez AJ,
    2. Scott D,
    3. Srikanth V,
    4. Ebeling P
    : Effect of vitamin D supplementation on measures of arterial stiffness: A systematic review and meta-analysis of randomized controlled trials. Clin Endocrinol (Oxf) 84: 645–657, 2016
    OpenUrlPubMed
  10. ↵
    1. Levin A,
    2. Tang M,
    3. Perry T,
    4. Zalunardo N,
    5. Beaulieu M,
    6. Dubland JA,
    7. Zerr K,
    8. Djurdjev O
    : Randomized controlled trial for the effect of vitamin D supplementation on vascular stiffness in CKD. Clin J Am Soc Nephrol 12: 1447–1460, 2017
  11. ↵
    1. Kendrick J,
    2. Andrews E,
    3. You Z,
    4. Moreau K,
    5. Nowak KL,
    6. Farmer-Bailey H,
    7. Seals DR,
    8. Chonchol M
    : Cholecalciferol, calcitriol and vascular function in CKD: A randomized, double-blind trial. Clin J Am Soc Nephrol 12: 1438–1446, 2017
  12. ↵
    1. Thadhani R,
    2. Appelbaum E,
    3. Pritchett Y,
    4. Chang Y,
    5. Wenger J,
    6. Tamez H,
    7. Bhan I,
    8. Agarwal R,
    9. Zoccali C,
    10. Wanner C,
    11. Lloyd-Jones D,
    12. Cannata J,
    13. Thompson BT,
    14. Andress D,
    15. Zhang W,
    16. Packham D,
    17. Singh B,
    18. Zehnder D,
    19. Shah A,
    20. Pachika A,
    21. Manning WJ,
    22. Solomon SD
    : Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: The PRIMO randomized controlled trial. JAMA 307: 674–684, 2012
    OpenUrlCrossRefPubMed
  13. ↵
    1. Wang AY,
    2. Fang F,
    3. Chan J,
    4. Wen YY,
    5. Qing S,
    6. Chan IH,
    7. Lo G,
    8. Lai KN,
    9. Lo WK,
    10. Lam CW,
    11. Yu CM
    : Effect of paricalcitol on left ventricular mass and function in CKD--the OPERA trial. J Am Soc Nephrol 25: 175–186, 2014
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. de Zeeuw D,
    2. Agarwal R,
    3. Amdahl M,
    4. Audhya P,
    5. Coyne D,
    6. Garimella T,
    7. Parving HH,
    8. Pritchett Y,
    9. Remuzzi G,
    10. Ritz E,
    11. Andress D
    : Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): A randomised controlled trial. Lancet 376: 1543–1551, 2010
    OpenUrlCrossRefPubMed
  15. ↵
    1. Zoccali C,
    2. Curatola G,
    3. Panuccio V,
    4. Tripepi R,
    5. Pizzini P,
    6. Versace M,
    7. Bolignano D,
    8. Cutrupi S,
    9. Politi R,
    10. Tripepi G,
    11. Ghiadoni L,
    12. Thadhani R,
    13. Mallamaci F
    : Paricalcitol and endothelial function in chronic kidney disease trial. Hypertension 64: 1005–1011, 2014
    OpenUrlCrossRefPubMed
  16. ↵
    1. Kumar V,
    2. Yadav AK,
    3. Lal A,
    4. Kumar V,
    5. Singhal M,
    6. Billot L,
    7. Gupta KL,
    8. Banerjee D,
    9. Jha V
    : A randomized trial of vitamin D supplementation on vascular function in CKD [published online ahead of print June 30, 2017]. J Am Soc Nephrol doi:10.1681/ASN.2017010003
  17. ↵
    1. Ketteler M,
    2. Block GA,
    3. Evenepoel P,
    4. Fukagawa M,
    5. Herzog CA,
    6. McCann L,
    7. Moe SM,
    8. Shroff R,
    9. Tonelli MA,
    10. Toussaint ND,
    11. Vervloet MG,
    12. Leonard MB
    : Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) guideline update: What’s changed and why it matters. Kidney Int 92: 26–36, 2017
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 12 (9)
Clinical Journal of the American Society of Nephrology
Vol. 12, Issue 9
September 07, 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
What Is the Role of Vitamin D Supplementation on Vascular Health in CKD?
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
What Is the Role of Vitamin D Supplementation on Vascular Health in CKD?
Nigel D. Toussaint, Irene Ruderman
CJASN Sep 2017, 12 (9) 1377-1379; DOI: 10.2215/CJN.07170717

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
What Is the Role of Vitamin D Supplementation on Vascular Health in CKD?
Nigel D. Toussaint, Irene Ruderman
CJASN Sep 2017, 12 (9) 1377-1379; DOI: 10.2215/CJN.07170717
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Footnotes
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Recurrent Hyperkalemia in Renin-Angiotensin-Aldosterone System Inhibitor (RAASi) Treatment
  • Postkidney Transplant Care and Health Outcomes of US Veterans
  • Leveraging Deep Learning to Improve Safety of Outpatient Hemodialysis
Show more Editorials

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • Randomized Controlled Trial for the Effect of Vitamin D Supplementation on Vascular Stiffness in CKD
  • Cholecalciferol, Calcitriol, and Vascular Function in CKD: A Randomized, Double-Blind Trial
  • PubMed
  • Google Scholar

Keywords

  • Dietary Supplements
  • Nutrition Therapy
  • vitamin D
  • Renal Insufficiency
  • Chronic
  • vitamin D deficiency

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire